ProKidney, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Judah Frommer from Morgan Stanley maintained a Hold rating on the stock and has a $3.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Judah Frommer has given his Hold rating due to a combination of factors, primarily reflecting both the promise and the extended timeline of ProKidney’s lead asset, rilparencel. While the company remains aligned with the FDA on an accelerated pathway and continues to advance the PROACT 1 trial, the reduction in confirmatory enrollment coupled with unchanged event targets implies the study will run longer before delivering definitive outcomes.
Frommer also notes that key value-inflecting catalysts, including mechanism-of-action data and enrollment milestones for both the accelerated and confirmatory analyses, are spread over 2026–2027, pushing meaningful readouts and any potential BLA submission into the outer years. Although management reaffirmed a cash runway into mid-2027, which limits near-term financing risk, the extended development horizon and reliance on future clinical data justify a more balanced stance, supporting a Hold rather than a more aggressive rating.
In another report released today, TipRanks – Google also reiterated a Hold rating on the stock with a $2.00 price target.
PROK’s price has also changed moderately for the past six months – from $2.710 to $2.080, which is a -23.25% drop .